Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies

Main Article Content

Lawrence Eichenfeld
Eric Simpson
Kim Papp
Jacek Szepietowski
Leon Kircik
Darryl Toth
Seth Forman
Michael Kuligowski
May Venturanza
Haobo Ren
Amy Paller

Keywords

atopic dermatitis

Abstract

N/A

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Silverberg NB, Durán-McKinster C. Dermatol Clin.
2017;35(3):351-363.

3. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

4. Oetjen LK, et al. Cell. 2017;171(1):217-228.

5. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

6. Papp K, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. Presented at: Revolutionizing Atopic Dermatitis Conference, June 13, 2021

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>